

Draft 2009 European (IUSTI/WHO) guideline on the management of lymphogranuloma venereum

HJC de Vries¹⁻³, SA Morré⁴⁻⁶ JA White⁷

1 STI outpatient clinic, Cluster Infectious Diseases, Health Service Amsterdam, Amsterdam, The Netherlands

2 Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

3 Centre for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, the Netherlands

4 Department of Pathology, Laboratory of Immunogenetics, and 5 Department of Internal Medicine, Section Infectious Diseases VU University Medical Center, Amsterdam, The Netherlands

6 Department of Medical Microbiology, Academic Hospital Maastricht, Maastricht, The Netherlands

7 Department of Genitourinary Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK

Address for Correspondence

HJC de Vries, STI outpatient clinic, Cluster Infectious Diseases, Health Service Amsterdam, Amsterdam, The Netherlands. e-mail: h.j.devries@amc.uva.nl

LYMPHOGRANULOMA VENEREUM (LGV)

LGV has re-emerged among European men who have sex with men (MSM) in recent years[1] and is probably endemic in this population where it is a relatively common cause of proctitis and occasional genital ulcer-adenopathy disease. Whilst occasional cases of heterosexual LGV are seen in Europe these have usually been imported from endemic countries.

Aetiology and transmission

- Causative pathogen: *Chlamydia trachomatis* types L1, L2, and L3. Additional variants have been described such as L2b, the strain currently found in MSM. In contrast to serovars A-K which remain confined to the mucosa, serovar L strains are invasive organisms that disseminate via underlying connective tissue and spread to regional lymph nodes.
- Worldwide, LGV is thought to account for 2 to 10% of GUD in areas such as India and Africa. In Western regions LGV is endemic among MSM, mainly those co-infected with HIV.[3] Heterosexual transmission has been described recently in Spain.[4]
- Neither the degree of infectiousness nor the reservoir of disease has been accurately defined, but heterosexual transmission has been attributed largely to asymptomatic female carriers and in the MSM population, asymptomatic rectal infection is the likely source of onward transmission.[3]

Clinical features

The disease course in heterosexuals usually follows three separate stages.

- Incubation period - one to four weeks
- Primary Lesion - small painless papule or pustule; may erode to form a small herpetiform ulcer. Usually heals within one week and often remains unnoticed. Mucopurulent discharge may be present, affecting the urethra in men and the cervix in women.
- Second stage: "inguinal stage" - begins 2 to 6 weeks after onset of primary lesion. Causes painful inflammation of the inguinal and/or femoral lymph nodes. Typically this produces unilateral enlargement, inflammation, suppuration and abscesses. These "buboes" may become fluctuant and rupture in one third of patients. Some patients develop the "groove sign", which results from enlargement of the inguinal nodes above and the femoral nodes below Poupart's ligament.
- Most men present during this second stage of disease; in contrast most women do not develop the characteristic inguinal lymphadenopathy. Women more often have primary involvement of the rectum, upper vagina, cervix, or posterior urethra; as these regions drain to the deep iliac or perirectal nodes, inguinofemoral lymphadenopathy is not seen. The resultant intra-abdominal or retroperitoneal lymphadenopathy may lead to symptoms of lower abdominal pain or low back pain.
- Constitutional symptoms, such as low-grade fever, chills, malaise, myalgias and arthralgias may present during the second stage of disease. In addition, systemic spread of *C. trachomatis* occasionally results in arthritis, pneumonitis or (peri) hepatitis. Rare systemic complications include cardiac involvement, aseptic meningitis and ocular inflammatory disease.
- A rare presentation is the pharyngeal syndrome affecting the mouth and throat. Cervical lymphadenopathy and buboes can occur.[5]
- LGV proctitis in MSM occurs as a primary manifestation of infection, usually presenting within a few weeks of sexual contact. It is characterised by severe symptoms of anorectal pain, haemopurulent discharge and bleeding *per rectum*; tenesmus and constipation are also seen due to the mucosal and perirectal oedema. Proctoscopic examination may reveal a distal granular or haemorrhagic proctitis with purulent exudate and mucosal ulceration. LGV proctitis is not usually accompanied by inguinofemoral lymphadenopathy; however radiological imaging may demonstrate pelvic node involvement.
- In the present LGV epidemic among MSM, symptomatology has varied in different populations, with UK cohorts showing almost all LGV to be symptomatic[6], in contrast to Dutch studies where a significant proportion of asymptomatic infection has been detected.[3, 7]
- The third stage of disease in LGV is often called the "anogenitoretal syndrome" and is more often present in women. Patients initially develop proctocolitis followed by peri-rectal abscess, fistulas, strictures and stenosis of the rectum, possibly leading to "lymphorrhoids" (haemorrhoid-like swellings of obstructed rectal lymphatic tissue). Without treatment, chronic

progressive lymphangitis leads to chronic oedema and sclerosing fibrosis, resulting in strictures and fistulas of the involved region, which can ultimately lead to elephantiasis, esthiomene and the frozen pelvis syndrome. If left untreated, LGV proctitis can lead to rectal stricture, with subsequent sequelae of soiling, pain, constipation and the possible development of mega colon.[8]

Diagnosis

- The diagnosis of LGV is confirmed by the detection of biovar-specific *C. trachomatis* DNA in ulcer material from primary anogenital lesions, rectal specimens (in suspected cases of anorectal LGV) or in bubo aspirates (in suspected cases inguinal LGV); historically LGV has been difficult to isolate from bubo aspirates in culture studies. (IV, C). Modern diagnostic approaches have been reviewed recently[9].
- Most modern laboratories follow a 2-step procedure:
 - First, a commercially available *C. trachomatis* NAAT test can be used to screen suspected samples. Although commercially available tests are not approved for extragenital sites, a large body of literature supports the use of these tests for the detection of rectal chlamydial infections.[7, 11-13] (III, B)
 - If *C. trachomatis* is detected, LGV biovar-specific DNA then needs to be detected from the same specimen. For this purpose two “in house” NAAT tests have been reported; firstly, a real-time PCR-based test that specifically detects all *C. trachomatis* LGV biovar strains[13] and more recently, a real-time quadriplex PCR-based assay which incorporates both LGV-specific and non-LGV-specific target sequences, a *C. trachomatis* plasmid target, and the human RNase P gene as an internal control[14]. (III, B)
- In case molecular diagnostic test facilities are not available a presumptive LGV diagnosis can be made using *Chlamydia* genus-specific serological assays. A high antibody titre in a patient with a clinical syndrome suggestive of LGV supports the diagnosis. Nonetheless, a low titre does not exclude LGV, nor does a high titre in a patient without LGV symptomatology confirm LGV infection.[15,16] (III, B)

Management

Information, explanation and advice for the patient

- Patients should be informed that LGV is an invasive bacterial infection that is sexually transmitted but curable with antibiotics. Left untreated it can have serious and permanent adverse sequelae. Most of these complications are preventable if treatment is initiated in the early stages. (IV, C)
- Symptoms should resolve within 1-2 weeks of commencing antibiotic therapy. (III, B)
- Patients should abstain from any sexual contact until they have completed therapy. (IV, C)

- Screening for other STIs including HIV should be offered prior to the commencement of therapy. (IV, C)

Therapy

Despite a paucity of robust evidence[17] regarding the efficacy of therapy for any rectal chlamydial infections (LGV or non-LGV), current guidelines recommend three weeks of oral doxycycline 100mg twice daily to treat LGV[18-20] and the vast majority of recent MSM case reports have observed complete responses to this therapy; shorter courses may not eradicate the organism[21].

- First line - doxycycline 100mg twice a day orally for 21 days. (III, B)
- Second line - erythromycin 500mg four times a day orally for 21 days. (III, B)

*Azithromycin in single- or multiple-dose regimens has also been proposed[22,23] but evidence is lacking to recommend this drug currently. (IV, C)

Adjunctive therapy

- If fluctuant buboes appear they should be aspirated promptly through healthy adjacent skin. (IV, C)
- Surgical incision of buboes is not usually recommended due to potential complications such as chronic sinus formation. (IV, C)
- Patients with residual fibrotic lesions or fistulae do not benefit from further courses of antibiotics so surgical repair, including reconstructive genital surgery, should be considered. (IV, C)

Partner notification

As LGV is sexually transmitted it is essential that partner notification is initiated when the diagnosis is made. Sexual contacts within the last 3 months should be offered testing for Chlamydia/LGV and empiric treatment with antibiotic therapy as above. (IV, C)

Follow-up

All patients diagnosed with LGV should be followed up at the end of treatment:

- to ensure resolution of symptoms and signs of infection
- to check that adequate partner notification has been completed
- to address any patient concerns

- to arrange suitable follow-up testing for syphilis and blood-borne viruses including hepatitis B, C and HIV

*In the recent MSM LGV epidemic incident cases of both HIV and hepatitis C[24] have been observed and serological testing should be offered for both infections after appropriate window periods have elapsed according to relevant local guidelines.

Prevention/health promotion

Patients diagnosed with LGV should be counselled regarding prevention of other STIs including HIV and hepatitis C:

- Offer regular sexual health screening including HIV testing
- Condom use should be demonstrated and promoted
- Hepatitis A and B vaccination for MSM
- Patients at risk of HIV infection should be advised of the availability of post exposure prophylaxis for HIV
- In particular, HIV-positive MSM should be made aware of recent trends in hepatitis C epidemiology and warned of the risks of unprotected anal sex, serosorting, recreational drug use and mucosally-traumatic sexual practices such as fisting. Enema use may be implicated in LGV transmission[3] so it is prudent to advise against sharing any such equipment and to wash equipment thoroughly after use.

Auditable Outcome Measures

- All cases of suspected LGV should be subjected to laboratory investigations. Target 100%.
- Sexual contacts within 3 months should be traced, tested and treated.
- HIV, syphilis, and hepatitis C serological testing should be offered, as well as screening for concomitant STIs
- Suspected or confirmed cases of LGV should be reported and relevant surveillance data collected according to local and national guidelines.

Rigor of development

The previous European IUSTI guideline titled “European Guideline for the Management of Tropical Genito-ulcerative diseases” from October 2001 was used as a basis for the current guideline.

MEDLINE and PubMed searches were performed from 2000 to December 2009 using MeSH headings “lymphogranuloma venereum” including all documents and subheadings. Additional searches were conducted using MeSH headings “LGV” and “Chlamydia trachomatis”.

References

1. Nieuwenhuis RF, Ossewaarde JM, Gotz HM, et al. Resurgence of lymphogranuloma

- venereum in Western Europe: an outbreak of *Chlamydia trachomatis* serovar I2 proctitis in The Netherlands among men who have sex with men. *Clin Infect Dis* **2004**; 39:996-1003.
2. Spaargaren J, Schachter J, Moncada J, et al. Slow epidemic of lymphogranuloma venereum L2b strain. *Emerg Infect Dis* **2005**; 11:1787-8.
 3. de Vries HJ, Van der Bij AK, Fennema JS, et al. Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. *Sex Transm Dis* **2008**; 35:203-8.
 4. de Munain JL, Ezpeleta G, Imaz M, et al. Two Lymphogranuloma Venereum Cases in a Heterosexual Couple in Bilbao (Spain). *Sex Transm Dis* **2008**.
 5. Perine PL, Stamm WE. Lymphogranuloma venereum. In: Holmes KK, Sparling PF, Mardh PA, et al., eds. *Sexually transmitted diseases*. 3 ed. New York: McGraw-Hill, **1999**:423-32.
 6. Ward H, Alexander S, Carder C et al. The prevalence of lymphogranuloma venereum infection in men who have sex with men: results of a multicentre case finding study. *Sex Transm Infect* **2009**; **85**:173-175
 7. Van der Bij AK, Spaargaren J, Morre SA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. *Clin Infect Dis* **2006**; 42:186-94.
 8. Pinski I, Saloojee N, Friedlich M. Lymphogranuloma venereum as a cause of rectal stricture. *Can J Surg* **2007**; 50:E31-E32.
 9. Herring A, Richens J. Part 2: Testing guidelines for individual sexually transmitted infections: Lymphogranuloma venereum. *Sex Transm Infect* **2006**; **82**:iv23-iv25
 10. Halse TA, Musser KA, Limberger RJ. A multiplexed real-time PCR assay for rapid detection of *Chlamydia trachomatis* and identification of serovar L-2, the major cause of Lymphogranuloma venereum in New York. *Mol Cell Probes* **2006**; 20:290-7.
 11. Hamill M, Benn P, Carder C, et al. The clinical manifestations of anorectal infection with lymphogranuloma venereum (LGV) versus non-LGV strains of *Chlamydia trachomatis*: a case-control study in homosexual men. *Int J STD AIDS* **2007**; 18:472-5.
 12. Jalal H, Stephen H, Alexander S, Carne C, Sonnex C. Development of real-time PCR assays for genotyping of *Chlamydia trachomatis*. *J Clin Microbiol* **2007**; 45:2649-53.
 13. Morre SA, Spaargaren J, Fennema JS, de Vries HJ, Coutinho RA, Pena AS. Real-time polymerase chain reaction to diagnose lymphogranuloma venereum. *Emerg Infect Dis* **2005**; 11:1311-2.
 14. Chen CY, Chi KH, Alexander S, Ison C, Ballard RC. A real-time quadriplex PCR assay for the diagnosis of rectal lymphogranuloma venereum (LGV) and non-LGV *Chlamydia trachomatis* infections. *Sex Transm Infect* **2008**; **84**:273-6.
 15. van der Snoek EM, Ossewaarde JM, van der Meijden WI, Mulder PG, Thio HB. The use of serological titres of IgA and IgG in (early) discrimination between rectal infection with non-lymphogranuloma venereum and lymphogranuloma venereum serovars of *Chlamydia trachomatis*. *Sex Transm Infect* **2007**; 83:330-4.

16. Smelov V, Morre SA, de VH. Are serological chlamydia-specific markers useful to detect asymptomatic cases of lymphogranuloma venereum proctitis? *Sex Transm Infect* **2008**; 84:77-8.
17. McLean CA, Stoner BP, Workowski KA. Treatment of lymphogranuloma venereum. *Clin Infect Dis* **2007**; **44** Suppl 3: S147-52.
18. Clinical Effectiveness Group of the British Association for Sexual Health and HIV (CEG/BASHH). **2006** National Guideline for the Management of Lymphogranuloma Venereum (LGV). Accessed online at: <http://www.bashh.org/guidelines> (6 December 2009).
19. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep* **2006** Aug 4;55(RR-11):1-94.
20. McMillan A, van Voorst Vader PC, de Vries HJ. The 2007 European Guideline (International Union against Sexually Transmitted Infections/World Health Organization) on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. *Int J STD AIDS* **2007**; 18:514 - 520.
21. de Vries HJ, Smelov V, Middelburg JG, et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. *Clin Infect Dis.* **2009** Mar 1; **48(5)**:e53-6
22. Nieuwenhuis RF, Ossewaarde JM, van der Meijden WI, Neumann HA. Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: effective treatment with 1 g azithromycin. *Sex Transm Infect* **2003**; **79(6)**: 453-5.
23. van Nieuwkoop C, Gooskens J, Smit VT et al. Lymphogranuloma venereum proctocolitis: mucosal T cell immunity of the rectum associated with chlamydial clearance and clinical recovery. *Gut* **2007**; **56(10)**: 1476-7.
24. Gotz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. *AIDS* **2005**;19(9):969-974.

Guideline editor

Prof Harald Moi

IUSTI/WHO European STD Guidelines Editorial Board

Dr Keith Radcliffe - Editor-in-Chief, Dr Karen Babayan, Dr Michel Janier, Dr Jorgen Skov Jensen, Prof. Harald Moi, Dr Raj Patel, Prof Jonathan Ross, Dr Jackie Sherrard, Dr Magnus Unemo, Dr Willem van der Meijden, Dr Simon Barton, Dr Lali Khotenashvili, Dr Marita van de Laar Prof. Martino Neumann, Dr Angela Robinson.

Appendix 1

Levels of evidence and grading of recommendations

Levels of Evidence

Ia Evidence obtained from meta-analysis of randomised controlled trials.

Ib Evidence obtained from at least one randomised controlled trial.

Ila Evidence obtained from at least one well designed study without randomisation.

IIb Evidence obtained from at least one other type of well designed quasi-experimental study.

III Evidence obtained from well designed non-experimental descriptive studies such as comparative studies, correlation studies, and case control studies.

IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.

Grading of Recommendations

A (Evidence levels Ia, Ib)

Requires at least one randomised control trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

B (Evidence levels IIa, IIb, III)

Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

C (Evidence IV)

Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

Appendix 2

Declarations of Interest

Declarations of interest:

HJC de Vries –none to

SA Morr 

JA White – none to declare